相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors
Hao-Yue Xiang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
MYC as a target for cancer treatment
Michael J. Duffy et al.
CANCER TREATMENT REVIEWS (2021)
Investigational drugs for the treatment of diffuse large B-cell lymphoma
Andrea Patriarca et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells
Yu-xiang Wang et al.
CELL DEATH & DISEASE (2021)
PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8+T cells and promoting fatty acid metabolism
Pu Sun et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
PI3K alpha inhibitors sensitize esophageal squamous cell carcinoma to radiation by abrogating survival signals in tumor cells and tumor microenvironment
Jia-jie Shi et al.
CANCER LETTERS (2019)
Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer
Yuxiang Wang et al.
CANCER BIOLOGY & MEDICINE (2019)
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma
Victor A. Chow et al.
BLOOD (2018)
Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kα-selective inhibitor CYH33 in breast cancer
Xue-ling Liu et al.
CANCER LETTERS (2018)
p110α Inhibition Overcomes Stromal Cell-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma
Jiyu Guan et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Bjoern Chapuy et al.
NATURE MEDICINE (2018)
BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc
Ning Li et al.
CELL DEATH & DISEASE (2018)
Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation
Ryan Raisner et al.
CELL REPORTS (2018)
BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors
Enrico Derenzini et al.
CELL REPORTS (2018)
6-OH-Phenanthroquinolizidine Alkaloid and Its Derivatives Exert Potent Anticancer Activity by Delaying S Phase Progression
Yuxiu Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
Zefang Tang et al.
NUCLEIC ACIDS RESEARCH (2017)
PI3Kδ inhibition causes feedback activation of PI3Kα in the ABC subtype of diffuse large B-cell lymphoma
Georgios N. Pongas et al.
ONCOTARGET (2017)
Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma
Anupama Reddy et al.
CELL (2017)
BET inhibitors: a novel epigenetic approach
D. B. Doroshow et al.
ANNALS OF ONCOLOGY (2017)
Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL
Tabea Erdmann et al.
BLOOD (2017)
The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now
Luis Miguel Juarez-Salcedo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT
Juliane Paul et al.
CANCER CELL (2017)
Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression
Hideaki Ogiwara et al.
CANCER DISCOVERY (2016)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Molecular Pathways: Targeting the PI3K Pathway in Cancer-BET Inhibitors to the Rescue
Elias E. Stratikopoulos et al.
CLINICAL CANCER RESEARCH (2016)
Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma
Deepanwita Sengupta et al.
EPIGENETICS (2015)
Telomerase regulates MYC-driven oncogenesis independent of its reverse transcriptase activity
Cheryl M. Koh et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
SnapShot: Diffuse Large B Cell Lymphoma
Laura Pasqualucci et al.
CANCER CELL (2014)
C646, a selective small molecule inhibitor of histone acetyltransferase p300, radiosensitizes lung cancer cells by enhancing mitotic catastrophe
Takahiro Oike et al.
RADIOTHERAPY AND ONCOLOGY (2014)
A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth
Xiang Wang et al.
ACTA PHARMACOLOGICA SINICA (2013)
Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing
Ryan D. Morin et al.
BLOOD (2013)
MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
Alexandra Valera et al.
HAEMATOLOGICA (2013)
Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models
Wenmin Hou et al.
ONCOLOGY REPORTS (2013)
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma
Silvia Bea et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing
Jens G. Lohr et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC
Rahul Nahar et al.
BLOOD (2011)
Life and death of transcriptional co-activator p300
Jihong Chen et al.
EPIGENETICS (2011)
Inactivating mutations of acetyltransferase genes in B-cell lymphoma
Laura Pasqualucci et al.
NATURE (2011)
Rearrangement of MYC Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab
Sharon Barrans et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Covalent histone modifications - miswritten, misinterpreted and mis-erased in human cancers
Ping Chi et al.
NATURE REVIEWS CANCER (2010)
A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia
Ming-Jer Huang et al.
EXPERIMENTAL HEMATOLOGY (2006)
Cutting edge: Constitutive B cell receptor signaling is critical for basal growth of B lymphoma
Murali Gururajan et al.
JOURNAL OF IMMUNOLOGY (2006)
The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma
PG Smith et al.
BLOOD (2005)
A crucial role for the p110δ subunit of phosphatidylinositol 3-kinase in B cell development and activation
E Clayton et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
分享论文
